Inequalities in immuno-oncology access across Europe
14 Dec 2017
Inequalities in immuno-oncology access across Europe
Measuring innovation and value in healthcare systems
Could personalised medicine increase inequality to medicine access?
The economics of personalised medicine in low and middle income countries
Creating a culture of shared data
Accelerating research to the bedside
Developing drugs for personalised medicine
The Innovative Medicines Initiative
Lenalidomide with rituximab for mantle cell lymphoma
Combination chemotherapy for multiple myeloma
Results of the AML 12 trial
Why we are not ready for personalised medicine